CAR-T Meeting 2022 | New indications for CAR-T therapies in hematological malignancies
Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Autonomous University of Barcelona, Barcelona, Spain, comments on the current status and future perspectives in chimeric antigen receptor T-cell (CAR-T) therapies for hematological malignancies. Whilst CAR-T therapies have been approved in the third-line setting for diffuse large B-cell lymphoma (DLBCL), recent data from key clinical trials has demonstrated the benefit of CAR-Ts over current standards of care (SOC) in the second-line setting. In addition, other ongoing clinical trials are reporting highly promising results for CAR-T therapies in multiple myeloma and adult acute lymphoblastic leukemia (ALL). It is expected that CAR-T therapies will be developed and approved for other hematological malignancies soon. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
